<p>A) Normal MCF10A cells exhibited a concentration-dependent decrease in BrdU incorporation (proliferation) when treated with 500 nM ouabain, 50 nM bufalin or 100 nM bufalin for 2 hours (p<0.01). MCF7, MCF10CA1, and MDA-MB-231 cells showed no significant decrease (p>0.05) in proliferation under comparable conditions. MDA-MB-231 cells treated with 50 nM or 100 nM bufalin had p-values of 0.057 and 0.061, respectively. B) High ouabain treatment (500 nM) for 24 hours caused a decrease in proliferation of MDA-MB-231 and MCF10CA1 cells, but no change to proliferation of MCF7 cells. Low ouabain or bufalin treatment had no effect on proliferation of any cancer cells tested.</p
The effect of CVMSCs on MDA-MB231 cells proliferation was assessed in vitro over 50 hour. C is MDA-M...
<p>(A) Cell growth curve was evaluated using trypan blue staining to measure viable cells at 24, 48 ...
<p>(A) Bufalin induced a dose- and time-dependent decrease in osteosarcoma cell growth. (B) Bufalin ...
<p>Normal 184D, 184A1, and MCF10A cells and tumorous MCF10CA1, MCF7, and MDA-MB-231 cells were treat...
<p>(A–D) Cells were seeded in 96-well plates and treated with different concentrations of bufalin fo...
Cell proliferation was evaluated by MTS assay and expressed as percentage value with respect to cont...
<p>(A–D) H929 cells were treated with 10 nM bufalin alone, or in combination with 50 nM topotecan, 1...
<p><b>A</b>, H460 lung cancer cells were treated with 1 µM CVT-11127 (CVT) or DMSO for 48 h in prese...
<p>Approximately 10<sup>4</sup> cells were seeded into microwell plates and allowed to grow over 4 d...
<p>Synergistic effect of K27 and bortezomib (BZ in the figure) (A, C, E, G) or CX-4945 and bortezomi...
<p>(A-D):48-h treatment with TM-025/TM-026 showed significant (P<0.0001; depicted with *) dose-depen...
<p>Lysates from MCF10A, MCF10CA1, and MDA-MB-231 cells treated with ouabain (Oua) or staurosporine (...
<p>Ouabain causes MCF10A cells to undergo apoptosis, but not MCF7, MDA-MB-231, or MCF10CA1 cells. DN...
<p>(A) Scatter plot of drug concentration <i>vs</i>. density of viable cells. (B) Scatter plot of dr...
<p>(A) Control and hUCBSC-treated glioma cells at different time points were analyzed for cell proli...
The effect of CVMSCs on MDA-MB231 cells proliferation was assessed in vitro over 50 hour. C is MDA-M...
<p>(A) Cell growth curve was evaluated using trypan blue staining to measure viable cells at 24, 48 ...
<p>(A) Bufalin induced a dose- and time-dependent decrease in osteosarcoma cell growth. (B) Bufalin ...
<p>Normal 184D, 184A1, and MCF10A cells and tumorous MCF10CA1, MCF7, and MDA-MB-231 cells were treat...
<p>(A–D) Cells were seeded in 96-well plates and treated with different concentrations of bufalin fo...
Cell proliferation was evaluated by MTS assay and expressed as percentage value with respect to cont...
<p>(A–D) H929 cells were treated with 10 nM bufalin alone, or in combination with 50 nM topotecan, 1...
<p><b>A</b>, H460 lung cancer cells were treated with 1 µM CVT-11127 (CVT) or DMSO for 48 h in prese...
<p>Approximately 10<sup>4</sup> cells were seeded into microwell plates and allowed to grow over 4 d...
<p>Synergistic effect of K27 and bortezomib (BZ in the figure) (A, C, E, G) or CX-4945 and bortezomi...
<p>(A-D):48-h treatment with TM-025/TM-026 showed significant (P<0.0001; depicted with *) dose-depen...
<p>Lysates from MCF10A, MCF10CA1, and MDA-MB-231 cells treated with ouabain (Oua) or staurosporine (...
<p>Ouabain causes MCF10A cells to undergo apoptosis, but not MCF7, MDA-MB-231, or MCF10CA1 cells. DN...
<p>(A) Scatter plot of drug concentration <i>vs</i>. density of viable cells. (B) Scatter plot of dr...
<p>(A) Control and hUCBSC-treated glioma cells at different time points were analyzed for cell proli...
The effect of CVMSCs on MDA-MB231 cells proliferation was assessed in vitro over 50 hour. C is MDA-M...
<p>(A) Cell growth curve was evaluated using trypan blue staining to measure viable cells at 24, 48 ...
<p>(A) Bufalin induced a dose- and time-dependent decrease in osteosarcoma cell growth. (B) Bufalin ...